Newsroom
Latest News
News
SERA REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS
Sera announced financial results for the second quarter of 2024 ended June 30, 2024.
News
Sera Announces Conference Call and Webcast of Second Quarter Fiscal Year 2024 Financial Results on August 7, 2024
Sera announced that it will report second quarter fiscal year 2024 financial results on Wednesday, August 7, 2024, after the close of the market.
News
Sera PreTRM® Test Prevention Strategy Demonstrates 18% Reduction in Severe Neonatal Morbidity and Mortality in Newly Published AVERT Trial
Sera Announces Publication of Positive AVERT PRETERM TRIAL Results in the International Peer-Reviewed Journal, Diagnostics
News
SERA ADDED TO RUSSELL 2000 AND 3000 INDEXES FOLLOWING CONCLUSION OF 2024 INDEXES ANNUAL RECONSTITUTION
Sera announced that as a result of the annual Rusell Reconstitution being finalized on June 28, 2024, the Company has been added to the Russell Small-Cap 2000 and Russell 3000 indexes
News
SERA EXPECTED TO BE ADDED TO RUSSELL 2000 AND 3000 INDEXES
Sera announced that it has been added to the preliminary list of the Russell Small-Cap 2000 and Russell 3000 indexes
News
SERA REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS
Sera announced financial results for the first quarter of 2024 ended March 31, 2024.
News
SERA REPORTS FOURTH QUARTER 2023 FINANCIAL RESULTS
Sera announced financial results for the fourth quarter and full year ended December 31, 2023.
News
Sera Announces Conference Call and Webcast of Fourth Quarter and Fiscal Year 2023 Financial Results on March 20, 2024
Sera announced that it will report fourth quarter and full year 2023 financial results on Wednesday, March 20
News
Sera To Present at TD Cowen 44th Annual Healthcare Conference
Sera announced that the company will present at the TD Cowen 44th Annual Healthcare Conference on Monday, March 4, 2024 at 2:50 p.m. ET.
News
SERA ANNOUNCES PRIMARY ENDPOINT CRITERIA MET
Sera today announced that the Data Safety Monitoring Board (DSMB) overseeing its pivotal PRIME study recommended stopping enrollment due to efficacy